Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy.
暂无分享,去创建一个
Nikolay Samusik | Garry P Nolan | G. Nolan | W. Fantl | G. Behbehani | Zach Bjornson | N. Samusik | Gregory K Behbehani | Bruno C Medeiros | Wendy J Fantl | Zach B Bjornson | B. Medeiros
[1] N. Russell,et al. FLT3‐ITD expression levels and their effect on STAT5 in AML with and without NPM mutations , 2009, British journal of haematology.
[2] M. Zöller,et al. Differential survival of AML subpopulations in NOD/SCID mice. , 2011, Experimental hematology.
[3] Peter O. Krutzik,et al. Intracellular phospho‐protein staining techniques for flow cytometry: Monitoring single cell signaling events , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[4] Sean C. Bendall,et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia , 2013, Nature Biotechnology.
[5] C. Bloomfield,et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] B. Falini,et al. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice. , 2010, Blood.
[7] T. Lister,et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. , 2005, Blood.
[8] I. Weissman,et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. , 2003, Genes & development.
[9] N. Socci,et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.
[10] K Wheatley,et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.
[11] M. Borowitz,et al. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. , 2012, Blood.
[12] O. Ornatsky,et al. Development of analytical methods for multiplex bio-assay with inductively coupled plasma mass spectrometry. , 2008, Journal of analytical atomic spectrometry.
[13] Bor-Sheng Ko,et al. Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations. , 2014, Leukemia research.
[14] Sean C. Bendall,et al. Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum , 2011, Science.
[15] Z. Darżynkiewicz,et al. Cell synchronization by inhibitors of DNA replication induces replication stress and DNA damage response: analysis by flow cytometry. , 2011, Methods in molecular biology.
[16] M. Carroll,et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. , 2011, The Journal of clinical investigation.
[17] J. Gribben,et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. , 2010, Blood.
[18] Eli R. Zunder,et al. Transient partial permeabilization with saponin enables cellular barcoding prior to surface marker staining , 2014, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[19] W. Plunkett,et al. Mechanisms of apoptosis induction by nucleoside analogs , 2003, Oncogene.
[20] Y. Guan,et al. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). , 2003, Blood.
[21] Eli R. Zunder,et al. Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm , 2015, Nature Protocols.
[22] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[23] C. Dunphy,et al. Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes. , 2006, Archives of pathology & laboratory medicine.
[24] Sean C. Bendall,et al. Normalization of mass cytometry data with bead standards , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[25] R. Hills,et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] I. Weissman,et al. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[27] J. Beyene,et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. , 2014, Leukemia research.
[28] Sylvie Chevret,et al. Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial , 2014, Oncotarget.
[29] Matthew R Clutter,et al. Single‐cell mass cytometry adapted to measurements of the cell cycle , 2012, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[30] C. Bloomfield,et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. , 1998, Cancer research.
[31] Naveed Yousuf,et al. Biological significance of cell cycle kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukaemia , 1991, British journal of haematology.
[32] Satoshi Tanaka,et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region , 2007, Nature Biotechnology.
[33] Sean C. Bendall,et al. Extracting a Cellular Hierarchy from High-dimensional Cytometry Data with SPADE , 2011, Nature Biotechnology.
[34] A. Martens,et al. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model , 2000, Leukemia.
[35] Peng Qiu,et al. Single‐cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3‐ITD‐mutated AML stem/progenitor cells , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[36] G. Wagemaker,et al. Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture. , 1996, Blood.
[37] J. Dick,et al. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.
[38] K. Döhner,et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] A. Tichelli,et al. Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia , 2010, Annals of Hematology.
[40] Irving L. Weissman,et al. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates , 2005, The Journal of experimental medicine.
[41] Jih-Luh Tang,et al. Characterization of CEBPA Mutations in Acute Myeloid Leukemia: Most Patients with CEBPA Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic Cells , 2005, Clinical Cancer Research.
[42] Anders Krogh,et al. Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients. , 2014, Blood.
[43] M. Caligiuri,et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.
[44] H. Dombret,et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study , 2012, The Lancet.
[45] D. Hogge,et al. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-)/HLA-DR-. , 1998, Blood.
[46] G. Schuurhuis,et al. Aberrant marker expression patterns on the CD34+CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission , 2007, Leukemia.
[47] T. Lister,et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. , 2006, Blood.
[48] Hartmut Döhner,et al. Acute myeloid leukaemia , 2006, The Lancet.
[49] S. Armstrong,et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML , 2013, Leukemia.
[50] Mark Munsell,et al. Engraftment of Acute Myeloid Leukemia in NOD/SCID Mice Is Independent of CXCR4 and Predicts Poor Patient Survival , 2004, Stem cells.